Evidence map›Paper›PMID 16847561›Full record

ArticleCellular & molecular biology letters2006

Camptothecin induces the transit of FasL trimers to the cell surface in apoptotic HEp-2 cells.

Esteban Meza-Lamas, Juan-José Bollain-y-Goytia, Roxana Ramírez-Sandoval, Sergio H Sánchez-Rodríguez, Erendira López-Robles, Esperanza Avalos-Díaz, Rafael Herrera-Esparza

Open access · hybridAbstract read
In one paragraph

Article in Cellular & molecular biology letters, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Esteban Meza-LamasDepartment of Molecular Biology, CBE, Universidad Autónoma de Zacatecas, Guadalpue, Zacatecas, Mexico.
Juan-José Bollain-y-Goytia
Roxana Ramírez-Sandoval
Sergio H Sánchez-Rodríguez
Erendira López-Robles
Esperanza Avalos-Díaz
Rafael Herrera-Esparza
Universidad Autónoma de Zacatecas "Francisco García Salinas" · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fas ligand (L) is a membrane protein from the tumor necrosis factor (TNF) family. It induces apoptosis upon contact with its Fas/CD95/APO1 receptor. Trimerization of FasL on the surface of effector cells is essential in the binding of the Fas trimer of the target cells. The receptor then recruits an adaptor and caspase-like proteins which lead apoptosis. This paper reports on the fate of FasL in HEp-2 cells committed to apoptosis by induction with campthotecin. Our main results demonstrated that in non-apoptotic cells, FasL aggregates in the cytoplasm forming trimers of 120 kDa. Apoptosis increases the trimeric FasL species, but also induces its dissociation into monomers of 35 kDa. In conclusion, camptothecin appears to perturb the Fas and FasL segregation in the cytoplasm by promoting the transit of FasL to the cell surface, thus fostering a process of autocrine or paracrine apoptosis. FasL is trimerized prior to Fas/FasL complex formation, and after apoptosis, FasL undergoes an intense turnover.

Indexed as

Amino Acid Chloromethyl KetonesApoptosisCamptothecinCaspase 3Cell Line, TumorDeoxyribonucleasesDNA FragmentationFas Ligand Proteinfas ReceptorHumansIn Situ Nick-End LabelingPoly-ADP-Ribose Binding ProteinsProtein Structure, QuaternaryProtein TransportSubcellular FractionsTranscription, GeneticAmino Acid Chloromethyl Ketonesbenzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketoneCamptothecinCaspase 3DeoxyribonucleasesDFFB protein, humanFas Ligand Proteinfas ReceptorPoly-ADP-Ribose Binding Proteins

Identifiers

PMID16847561
PMCPMC6472842
OpenAlexW1998153461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.